

# Table of Contents

<b>1 Principles of Vaccination</b>	
Immunology and Vaccine-Preventable Diseases . . . . .	1
Classification of Vaccines . . . . .	4
Selected References . . . . .	7
<b>2 General Recommendations on Immunization</b>	
Timing and Spacing of Vaccines . . . . .	9
Adverse Reactions Following Vaccination . . . . .	15
Contraindications and Precautions to Vaccination . . . . .	16
Invalid Contraindications to Vaccination . . . . .	23
Screening for Contraindications and Precautions to Vaccination . . . . .	27
Selected References . . . . .	30
<b>3 Immunization Strategies for Healthcare Practices and Providers</b>	
The Need for Strategies to Increase Immunization Levels . . . . .	31
The AFIX Approach . . . . .	33
Other Essential Strategies . . . . .	38
Selected References . . . . .	43
<b>4 Vaccine Safety</b>	
The Importance of Vaccine Safety Programs . . . . .	45
Sound Immunization Recommendations and Policy . . . . .	46
Methods of Monitoring Vaccine Safety . . . . .	47
Vaccine Injury Compensation . . . . .	52
The Immunization Provider's Role . . . . .	52
Selected References . . . . .	57
<b>5 Diphtheria</b>	
Corynebacterium diphtheriae . . . . .	59
Pathogenesis . . . . .	59
Clinical Features . . . . .	59
Complications . . . . .	61
Laboratory Diagnosis . . . . .	61
Medical Management . . . . .	62
Epidemiology . . . . .	63
Secular Trends in the United States . . . . .	64
Diphtheria Toxoid . . . . .	65
Vaccination Schedule and Use . . . . .	66
Contraindications and Precautions to Vaccination . . . . .	67
Adverse Reactions Following Vaccination . . . . .	67
Vaccine Storage and Handling . . . . .	68
Suspect Case Investigation and Control . . . . .	68
Selected References . . . . .	69

## Milestones in the History of Vaccination

**1870**

Louis Pasteur creates the first live attenuated bacterial vaccine (chicken cholera)

**1884**

Pasteur creates the first live attenuated viral vaccine (rabies)

**1885**

Pasteur first uses rabies vaccine in a human

**1887**

Institut Pasteur established

**1900**

Paul Ehrlich formulates receptor theory of immunity

## Table of Contents

### 6 *Haemophilus influenzae*

Haemophilus influenzae	71
Pathogenesis	71
Clinical Features	73
Laboratory Diagnosis	73
Medical Management	74
Epidemiology	74
Secular Trends in the United States	75
Haemophilus influenzae type b Vaccines	76
Vaccination Schedule and Use	78
Combination Vaccines	80
Contraindications and Precautions to Vaccination	82
Adverse Reactions Following Vaccination	82
Vaccine Storage and Handling	82
Surveillance and Reporting of Hib Disease	83
Selected References	83

### 7 Hepatitis A

Hepatitis A Virus	85
Pathogenesis	85
Clinical Features	86
Complications	86
Laboratory Diagnosis	86
Medical Management	87
Epidemiology	87
Secular Trends in the United States	89
Case Definition	90
Hepatitis A Vaccine	90
Vaccination Schedule and Use	91
Contraindications and Precautions to Vaccination	95
Adverse Reactions Following Vaccination	96
Vaccine Storage and Handling	96
Postexposure Prophylaxis	96
Selected References	96

### 8 Hepatitis B

Hepatitis B Virus	99
Clinical Features	100
Complications	101
Laboratory Diagnosis	101
Medical Management	103
Epidemiology	103
Secular Trends in the United States	105
Hepatitis B Prevention Strategies	107

## Milestones in the History of Vaccination

**1901**  
First Nobel Prize in Medicine  
to von Behring for  
diphtheria antitoxin

**1909**  
Theobald Smith discovers a method  
for inactivating  
diphtheria toxin

**1919**  
Calmette and Guerin create BCG,  
the first live attenuated  
bacterial vaccine for humans

**1923**  
First whole-cell pertussis vaccine tested  
Gaston Ramon develops  
diphtheria toxoid

**1926**  
Ramon and Christian Zoeller  
develop tetanus toxoid

## Table of Contents

Hepatitis B Vaccine . . . . .	107
Vaccination Schedule and Use . . . . .	110
Serologic Testing of Vaccine Recipients . . . . .	115
Postexposure Management . . . . .	118
Contraindications and Precautions to Vaccination . . . . .	121
Adverse Reactions Following Vaccination . . . . .	121
Vaccine Storage and Handling . . . . .	122
Selected References . . . . .	122

### 9 Human Papillomavirus

Human Papillomavirus . . . . .	123
Pathogenesis . . . . .	123
Clinical Features . . . . .	124
Laboratory Diagnosis . . . . .	124
Medical Management . . . . .	125
Epidemiology . . . . .	125
Disease Burden in the United States . . . . .	126
Prevention . . . . .	127
Human Papillomavirus Vaccine . . . . .	127
Vaccination Schedule and Use . . . . .	129
Contraindications and Precautions to Vaccination . . . . .	131
Adverse Reactions Following Vaccination . . . . .	131
Vaccine Storage and Handling . . . . .	132
Selected References . . . . .	132

### 10 Influenza

Influenza Virus . . . . .	135
Pathogenesis . . . . .	137
Clinical Features . . . . .	137
Complications . . . . .	138
Impact of Influenza . . . . .	138
Laboratory Diagnosis . . . . .	139
Epidemiology . . . . .	140
Secular Trends in the United States . . . . .	140
Influenza Vaccine . . . . .	141
Vaccination Schedule and Use . . . . .	143
Contraindications and Precautions to Vaccination . . . . .	147
Adverse Reactions Following Vaccination . . . . .	148
Vaccine Storage and Handling . . . . .	150
Year 2010 Objectives and Coverage Levels . . . . .	151
Strategies for Improving Influenza Vaccine Coverage . . . . .	151
Antiviral Agents for Influenza . . . . .	152
Nosocomial Influenza Control . . . . .	153
Influenza Surveillance . . . . .	153
Selected References . . . . .	154

## Milestones in the History of Vaccination

**1927**  
Yellow fever virus isolated

**1931**  
Goodpasture describes a  
technique for viral culture  
in hens' eggs

**1936**  
Thomas Francis and Thomas Magill  
develop the first  
inactivated influenza vaccine

**1948**  
John Enders and colleagues  
isolate Lansing Type II poliovirus in  
human cell line

**1954**  
Enders and Peebles isolate measles virus  
Francis Field Trial  
of inactivated polio vaccine

## Table of Contents

### 11 Measles

Measles Virus . . . . .	157
Pathogenesis . . . . .	157
Clinical Features . . . . .	158
Complications . . . . .	158
Laboratory Diagnosis . . . . .	160
Epidemiology . . . . .	161
Secular Trends in the United States . . . . .	162
Classification of Measles Cases . . . . .	165
Measles Vaccine . . . . .	165
Vaccination Schedule and Use . . . . .	167
Contraindications and Precautions to Vaccination . . . . .	170
Adverse Reactions Following Vaccination . . . . .	173
Vaccine Storage and Handling . . . . .	174
Selected References . . . . .	175

### 12 Meningococcal Disease

Neisseria meningitidis . . . . .	177
Pathogenesis . . . . .	178
Clinical Features . . . . .	178
Laboratory Diagnosis . . . . .	179
Medical Management . . . . .	179
Epidemiology . . . . .	180
Secular Trends in the United States . . . . .	180
Meningococcal Vaccines . . . . .	181
Vaccination Schedule And Use . . . . .	183
Contraindications and Precautions to Vaccination . . . . .	185
Adverse Reactions Following Vaccination . . . . .	185
Vaccine Storage and Handling . . . . .	186
Surveillance and Reporting of Meningococcal Disease . . . . .	186
Antimicrobial Chemoprophylaxis . . . . .	186
Selected References . . . . .	187

### 13 Mumps

Mumps Virus . . . . .	189
Pathogenesis . . . . .	189
Clinical Features . . . . .	189
Complications . . . . .	190
Laboratory Diagnosis . . . . .	191
Epidemiology . . . . .	191
Secular Trends in the United States . . . . .	192
Case Definition . . . . .	192
Mumps Vaccine . . . . .	193
Vaccination Schedule and Use . . . . .	193

## Milestones in the History of Vaccination

**1955**  
Inactivated polio vaccine  
licensed

**1961**  
Human diploid cell line  
developed

**1963**  
Measles vaccine licensed  
Trivalent oral polio vaccine licensed

**1965**  
Bifurcated needle for  
smallpox vaccine licensed

**1966**  
World Health Assembly calls for  
global smallpox eradication

## Table of Contents

Contraindications and Precautions to Vaccination .....	195
Adverse Reactions Following Vaccination .....	196
Vaccine Storage and Handling .....	196
Selected References .....	197
<b>14 Pertussis</b>	
Bordetella pertussis .....	199
Pathogenesis .....	199
Clinical Features .....	199
Complications .....	200
Laboratory Diagnosis .....	201
Medical Management .....	202
Epidemiology .....	203
Secular Trends in the United States .....	203
Case Definition .....	205
Pertussis Vaccines .....	205
Vaccination Schedule and Use .....	207
Combination Vaccines Containing DTaP .....	210
Other DTaP Issues .....	212
Contraindications and Precautions to Vaccination .....	213
Adverse Reactions Following Vaccination .....	214
Vaccine Storage and Handling .....	216
Selected References .....	216
<b>15 Pneumococcal Disease</b>	
Streptococcus pneumoniae .....	217
Clinical Features .....	218
Laboratory Diagnosis .....	220
Medical Management .....	221
Epidemiology .....	221
Secular Trends in the United States .....	222
Pneumococcal Vaccines .....	222
Vaccination Schedule and Use .....	224
Contraindications and Precautions to Vaccination .....	227
Adverse Reactions Following Vaccination .....	228
Vaccine Storage and Handling .....	228
Goals and Coverage Levels .....	229
Selected References .....	229
<b>16 Poliomyelitis</b>	
Poliovirus .....	231
Pathogenesis .....	231
Clinical Features .....	232
Laboratory Diagnosis .....	233

### Milestones in the History of Vaccination ➔

**1967**  
Maurice Hilleman develops  
Jeryl Lynn strain of mumps virus

**1969**  
Stanley Plotkin develops RA27/3  
strain of rubella vaccine virus

**1971**  
MMR vaccine licensed

**1977**  
Last indigenous case of smallpox  
(Somalia)

**1979**  
Last wild poliovirus  
transmission in the U.S.

## Table of Contents

Epidemiology . . . . .	233
Secular Trends in the United States . . . . .	234
Poliovirus Vaccines . . . . .	235
Vaccination Schedule and Use . . . . .	237
Polio Vaccination of Adults . . . . .	238
Contraindications And Precautions To Vaccination . . . . .	239
Adverse Reactions Following Vaccination . . . . .	240
Vaccine Storage and Handling . . . . .	241
Outbreak Investigation and Control . . . . .	241
Polio Eradication . . . . .	242
Postpolio Syndrome . . . . .	243
Selected References . . . . .	243

### 17 Rotavirus

Rotavirus . . . . .	245
Pathogenesis . . . . .	245
Clinical Features . . . . .	246
Complications . . . . .	246
Laboratory Diagnosis . . . . .	246
Epidemiology . . . . .	247
Secular Trends in the United States . . . . .	248
Rotavirus Vaccines . . . . .	248
Vaccine Effectiveness . . . . .	250
Duration of Immunity . . . . .	250
Vaccination Schedule and Use . . . . .	251
Contraindications and Precautions to Vaccination . . . . .	252
Adverse Reactions Following Vaccination . . . . .	254
Vaccine Storage and Handling . . . . .	255
Rotavirus Surveillance . . . . .	255
Selected References . . . . .	256

### 18 Rubella

Rubella Virus . . . . .	257
Pathogenesis . . . . .	257
Clinical Features . . . . .	257
Complications . . . . .	258
Congenital Rubella Syndrome . . . . .	258
Laboratory Diagnosis . . . . .	259
Epidemiology . . . . .	260
Secular Trends in the United States . . . . .	261
Classification of Rubella Cases . . . . .	262
Rubella Vaccine . . . . .	263
Vaccination Schedule and Use . . . . .	264

## Milestones in the History of Vaccination

**1981**  
First hepatitis B  
vaccine licensed

**1983**  
Smallpox vaccine withdrawn  
from civilian market

**1986**  
First recombinant vaccine  
licensed (hepatitis B)  
National Childhood Vaccine Injury Act

**1989**  
Two-dose measles vaccine  
recommendation

**1990**  
First polysaccharide conjugate  
vaccine licensed  
(*Haemophilus influenzae* type b)

## Table of Contents

Rubella Immunity . . . . .	266
Contraindications and Precautions to Vaccination . . . . .	267
Adverse Reactions Following Vaccination . . . . .	268
Rubella Vaccination of Women of Childbearing Age . . . . .	269
Vaccine Storage and Handling . . . . .	270
Strategies to Decrease Rubella and CRS . . . . .	270
Selected References . . . . .	271

### 19 Tetanus

Clostridium tetani . . . . .	273
Pathogenesis . . . . .	274
Clinical Features . . . . .	274
Complications . . . . .	275
Laboratory Diagnosis . . . . .	275
Medical Management . . . . .	275
Wound Management . . . . .	276
Epidemiology . . . . .	276
Secular Trends in the United States . . . . .	277
Tetanus Toxoid . . . . .	278
Vaccination Schedule and Use . . . . .	279
Contraindications and Precautions to Vaccination . . . . .	280
Adverse Reactions Following Vaccination . . . . .	281
Vaccine Storage and Handling . . . . .	281
Selected References . . . . .	282

### 20 Varicella

Varicella Zoster Virus . . . . .	283
Pathogenesis . . . . .	283
Clinical Features . . . . .	283
Complications . . . . .	285
Laboratory Diagnosis . . . . .	286
Epidemiology . . . . .	288
Secular Trends in the United States . . . . .	289
Vaccines Containing Varicella Virus . . . . .	290
Vaccination Schedule and Use . . . . .	293
Varicella Immunity . . . . .	296
Contraindications and Precautions to Vaccination . . . . .	297
Zoster Vaccine . . . . .	299
Adverse Reactions Following Vaccination . . . . .	300
Transmission of Varicella Vaccine Virus . . . . .	302
Vaccine Storage and Handling . . . . .	302
Varicella Zoster Immune Globulin . . . . .	303
Selected References . . . . .	304

## Milestones in the History of Vaccination

<b>1994</b> Polio elimination certified in the Americas Vaccines for Children program begins	<b>1995</b> Varicella vaccine licensed Hepatitis A vaccine licensed First harmonized childhood immunization schedule published	<b>1996</b> Acellular pertussis vaccine licensed for infants	<b>1997</b> Sequential polio vaccination recommended	<b>1998</b> First rotavirus vaccine licensed
---	--	--	--	--

# Table of Contents

## APPENDICES

### A Schedules and Recommendations

Immunization Schedules on the Web . . . . .	A-1
Childhood Immunization Schedule 2009 . . . . .	A-2
Adult Immunization Schedule 2006–2009 . . . . .	A-5
Recommended Minimum Ages and Intervals . . . . .	A-8
Summary of Recommendations for	
Childhood & Adolescent Immunizations . . . . .	A-10
Summary of Recommendations for Adult Immunizations . . . . .	A-13
Antibody—Live Vaccine Interval Table . . . . .	A-16
Healthcare Worker Vaccination Recommendations . . . . .	A-17
Immunization of Immunocompromised Patients Tables . . . . .	A-18

### B Vaccines

U.S. Vaccines . . . . .	B-1
Selected Discontinued U.S. Vaccines . . . . .	B-6
Vaccine Excipient and Media Summary, by Excipient . . . . .	B-8
Vaccine Excipient and Media Summary, by Vaccine . . . . .	B-15
Thimerosal Content in Some U.S. Licensed Vaccines . . . . .	B-20
Pediatric/VFC Vaccine Price List . . . . .	B-21
Adult Vaccine Price List . . . . .	B-23
Influenza Vaccine Price List . . . . .	B-23
Foreign Language Terms . . . . .	B-24

### C Vaccine Storage and Handling

Vaccine Storage & Handling Recommendations (2009) . . . . .	C-1
Manufacturer Quality Control Phone Numbers . . . . .	C-19
Checklist for Safe Vaccine Handling & Storage . . . . .	C-20
Vaccine Handling Tips . . . . .	C-21
Sample Refrigerator Warning Signs . . . . .	C-22

### D Vaccine Administration

"Vaccine Administration" Guidelines . . . . .	D-1
Skills Checklist for Immunization . . . . .	D-16
Immunization Site Maps . . . . .	D-18
"Comforting Restraint" for Immunizations . . . . .	D-23
Injectable Vaccine Administration: Birth–6 Years . . . . .	D-24
Injectable Vaccine Administration: 7–18 Years . . . . .	D-26
Medical Management of	
Vaccine Reactions (Children & Teens) . . . . .	D-28
Medical Management of Vaccine Reactions (Adults) . . . . .	D-30

#### 1999

Exclusive use of inactivated polio vaccine recommended  
Rotavirus vaccine withdrawn

#### 2000

Pneumococcal conjugate vaccine licensed for infants

#### 2003

Live attenuated influenza vaccine licensed

#### 2004

Inactivated influenza vaccine recommended for all children 6–23 months of age

#### 2004

Indigenous transmission of rubella virus interrupted



## Table of Contents

### **E Vaccine Information Statements**

It's Federal Law . . . . .	E-1
Instructions for Use of VISs . . . . .	E-2
How to Get Vaccine Information Statements . . . . .	E-3
VIS Questions and Answers . . . . .	E-4
CDC's Vaccine Information Statement Webpage . . . . .	E-8

### **F Vaccine Safety**

The Vaccine Adverse Event Reporting System (VAERS) . . . . .	F-1
Table of Reportable Events Following Vaccination . . . . .	F-2
Vaccine Adverse Event Reporting System (VAERS) Form . . . . .	F-4
The Vaccine Injury Compensation Program (VICP) . . . . .	F-6
The VICP Vaccine Injury Table . . . . .	F-7
Qualification and Aids to Interpretation of the Vaccine Injury Table . . . . .	F-8

### **G Data and Statistics**

Reported Cases and Deaths from Vaccine-Preventable Diseases: 1950–2008 . . . . .	G-1
Impact of Vaccines in the 20th & 21th Centuries . . . . .	G-7
Vaccine Coverage Levels: 1962–2007 . . . . .	G-8

### **H Immunization Resources**

National Immunization Contacts and Resources . . . . .	H-1
IAC Online Directory of Immunization Resources . . . . .	H-2
Sample IAC Print Materials . . . . .	H-3
IAC Express Information Sheet . . . . .	H-4
"Immunization Techniques" Video . . . . .	H-5
Storage and Handling Toolkit . . . . .	H-6
State and Local Immunization Grantee Contact Information . . . . .	H-7

## Milestones in the History of Vaccination ➔

**2005**  
Acellular pertussis vaccines  
licensed for adolescents  
and adults

**2005**  
MMR-varicella (MMRV) licensed

**2006**  
Second generation rotavirus  
vaccine licensed

**2006**  
First human papillomavirus  
vaccine licensed

**2006**  
First herpes zoster vaccine  
licensed

## Vaccines and Related Products Distributed in the United States

Vaccine/Biologic	Brand Name	Manufacturer	Type	How Supplied
Diphtheria, Tetanus, acellular Pertussis	Infanrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus, acellular Pertussis	Tripedia®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis	Daptacel®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis + Hib	TriHIBit®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis +Hep B + IPV	Pediarix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus, acellular Pertussis + Hib + IPV	Pentacel®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis + IPV	Kinrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus (DT; ped <7yrs, P-free)	generic	sanofi-pasteur	Inactivated	single-dose vial
Tetanus, diphtheria, adsorbed (Td; >7yrs, P-free)	Decavac®	sanofi-pasteur	Inactivated	single-dose syringe
Tetanus, diphtheria, adsorbed (Td; >7yrs)	generic	Mass Biologic Labs	Inactivated	15-dose vial
Tetanus, diphtheria, acellular Pertussis (Tdap; 10-64 yrs)	Boostrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Tetanus, diphtheria, acellular Pertussis (Tdap; 11-64 yrs)	Adacel™	sanofi-pasteur	Inactivated	single-dose vial
Tetanus toxoid (TT; >7 yrs) adsorbed	generic	sanofi-pasteur	Inactivated	10-dose vial
Tetanus toxoid (TT; adult booster use only)	generic	sanofi-pasteur	Inactivated	15-dose vial
Tetanus immune globulin (TIG)	HyperTET™	Talecris	Human immunoglobulin	single-dose syringe
<i>Haemophilus influenzae</i> type b (PRP-T)	ActHIB®	sanofi-pasteur	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (HbOC)	HibTITER®	Wyeth	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (PRP-OMP)	PedvaxHIB®	Merck	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (PRP-OMP) + Hep B	Comvax®	Merck	Inactivated	single-dose vial
Hepatitis A: ped/adol & adult formulations	Havrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Hepatitis A: ped/adol & adult formulations	Vaqta®	Merck	Inactivated	single-dose vial or syringe
Hepatitis A immune globulin	GamaSTAN™	Talecris	Human immunoglobulin	2 mL and 10 mL vials
Hepatitis B: ped/adol & adult formulations	Engerix-B®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Hepatitis B: ped/adol & adult formulations	Recombivax HB®	Merck	Inactivated	single-dose vial
Hepatitis B dialysis formulation	Recombivax HB®	Merck	Inactivated	single-dose vial
Hepatitis B immune globulin (HBIG)	HyperHEP B™	Talecris	Human immunoglobulin	1 mL syringe, 1 mL or 5 mL vial
Hepatitis B immune globulin (HBIG): ped formulation	HyperHEP B™	Talecris	Human immunoglobulin	single-dose 0.5 mL neonatal syringe
Hepatitis B immune globulin (HBIG)	Nabi-HB®	Nabi	Human immunoglobulin	single-dose vial
Hepatitis A & B: adult formulation	Twinrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Human papillomavirus (HPV)	Gardasil®	Merck	Inactivated	single-dose vial or syringe
Influenza (trivalent inactivated influenza vaccine [TIV])	Fluarix®	GlaxoSmithKline	Inactivated	10 single-dose syringes
Influenza (live attenuated influenza vaccine [LAIV])	FluMist®	Medimmune	Live, intranasal	10 single-use sprayers
Influenza (TIV)	Afluria®	CSL Biotherapies	Inactivated	single-dose syringe & 10-dose vial
Influenza (TIV)	Fluvirin®	Novartis	Inactivated	single-dose syringe & 10-dose vial
Influenza (TIV)	Fluzone®	sanofi-pasteur	Inactivated	10-dose vial
Influenza (TIV; >36 mos; no preservative)	Fluzone®	sanofi-pasteur	Inactivated	single-dose syringe (0.5 mL)
Influenza (TIV; ped 6-35 mos; no preservative)	Fluzone®	sanofi-pasteur	Inactivated	single-dose syringe (0.25 mL)
Influenza (TIV; >18 yrs)	FluLaval™	GlaxoSmithKline	Inactivated	10-dose vial
Measles, Mumps, Rubella (MMR)	M-M-R II®	Merck	Live, attenuated	single-dose vial
Measles, Mumps, Rubella + Varicella (MMRV)	ProQuad®	Merck	Live, attenuated	single-dose vial
Meningococcal conjugate (AC/Y/W-135)	Menactra®	sanofi-pasteur	Inactivated	single-dose vial
Meningococcal polysaccharide (AC/Y/W-135)	Menomune®	sanofi-pasteur	Inactivated	single-dose vial
Pneumococcal conjugate, 7-valent	Prevnar®	Wyeth	Inactivated	single-dose vial
Pneumococcal polysaccharide, 23-valent	Pneumovax 23®	Merck	Inactivated	single-dose vial or 5-dose vial
Polio (IPV)	IPOL®	sanofi-pasteur	Inactivated	single-dose syringe or 10-dose vial
Rotavirus	RotaTeq®	Merck	Live, oral	single-dose tube
Rotavirus	Rotarix®	GlaxoSmithKline	Live, oral	single-dose tube
Varicella	Varivax®	Merck	Live, attenuated	single-dose vial
Varicella Zoster Immune Globulin (VZIG) (IND)	VariZIG™	Cangene	Human Immunoglobulin	125-U vial
Zoster	Zostavax®	Merck	Live, attenuated	single-dose vial
Anthrax, adsorbed	BioThrax™	BioPort	Inactivated	multi-dose vial
Japanese encephalitis	JE-VAX®	sanofi-pasteur	Inactivated	single-dose vial
Rabies	Imovax®	sanofi-pasteur	Inactivated	single-dose vial
Rabies	RabAvert®	Novartis	Inactivated	single-dose vial
Rabies Immune Globulin (RIG)	Imogam Rabies-HT®	sanofi-pasteur	Human immunoglobulin	2 mL and 10 mL vials
Rabies Immune Globulin (RIG)	HyperRAB™	Talecris	Human immunoglobulin	2 mL and 10 mL vials
Typhoid VI polysaccharide	Typhim Vi®	sanofi-pasteur	Inactivated	single-dose syringe and 20-dose vial
Typhoid, live oral Ty21a	Vivotif®	Berna	Live, attenuated	4-capsule package
Yellow Fever	YF-Vax®	sanofi-pasteur	Live, attenuated	single- and 5-dose vial

# Diphtheria

## Diphtheria

Diphtheria is an acute, toxin-mediated disease caused by the bacterium *Corynebacterium diphtheriae*. The name of the disease is derived from the Greek *diphthera*, meaning leather hide. The disease was described in the 5th century BCE by Hippocrates, and epidemics were described in the 6th century AD by Aetius. The bacterium was first observed in diphtheritic membranes by Klebs in 1883 and cultivated by Löffler in 1884. Antitoxin was invented in the late 19th century, and toxoid was developed in the 1920s.

## *Corynebacterium diphtheriae*

*C. diphtheriae* is an aerobic gram-positive bacillus. Toxin production (toxigenicity) occurs only when the bacillus is itself infected (lysogenized) by a specific virus (bacteriophage) carrying the genetic information for the toxin (tox gene). Only toxigenic strains can cause severe disease.

Culture of the organism requires selective media containing tellurite. If isolated, the organism must be distinguished in the laboratory from other *Corynebacterium* species that normally inhabit the nasopharynx and skin (e.g., diphtheroids).

*C. diphtheriae* has three biotypes—*gravis*, *intermedius*, and *mitis*. The most severe disease is associated with the *gravis* biotype, but any strain may produce toxin. All isolates of *C. diphtheriae* should be tested by the laboratory for toxigenicity.

## Pathogenesis

Susceptible persons may acquire toxigenic diphtheria bacilli in the nasopharynx. The organism produces a toxin that inhibits cellular protein synthesis and is responsible for local tissue destruction and membrane formation. The toxin produced at the site of the membrane is absorbed into the bloodstream and then distributed to the tissues of the body. The toxin is responsible for the major complications of myocarditis and neuritis and can also cause low platelet counts (thrombocytopenia) and protein in the urine (proteinuria).

Clinical disease associated with non-toxin-producing strains is generally milder. While rare severe cases have been reported, these may actually have been caused by toxigenic strains that were not detected because of inadequate culture sampling.

## Clinical Features

The incubation period of diphtheria is 2–5 days (range, 1–10 days).

Disease can involve almost any mucous membrane. For clinical purposes, it is convenient to classify diphtheria into a number of manifestations, depending on the site of disease.

### Diphtheria

- Greek *diphthera* (leather hide)
- Recognized by Hippocrates in 5th century BCE
- Epidemics described in 6th century
- *C. diphtheriae* described by Klebs in 1883
- Toxoid developed in 1920s

5

### *Corynebacterium diphtheriae*

- Aerobic gram-positive bacillus
- Toxin production occurs only when *C. diphtheriae* infected by virus (phage) carrying tox gene
- If isolated, must be distinguished from normal diphtheroid

### Diphtheria Clinical Features

- Incubation period 2-5 days (range, 1-10 days)
- May involve any mucous membrane
- Classified based on site of infection
  - anterior nasal
  - pharyngeal and tonsillar
  - laryngeal
  - cutaneous
  - ocular
  - genital

# Diphtheria

5

## Pharyngeal and Tonsillar Diphtheria

- Insidious onset of exudative pharyngitis
- Exudate spreads within 2-3 days and may form adherent membrane
- Membrane may cause respiratory obstruction
- Fever usually not high but patient appears toxic

## Anterior Nasal Diphtheria

The onset of anterior nasal diphtheria is indistinguishable from that of the common cold and is usually characterized by a mucopurulent nasal discharge (containing both mucus and pus) which may become blood-tinged. A white membrane usually forms on the nasal septum. The disease is usually fairly mild because of apparent poor systemic absorption of toxin in this location, and it can be terminated rapidly by antitoxin and antibiotic therapy.

## Pharyngeal and Tonsillar Diphtheria

The most common sites of diphtheria infection are the pharynx and the tonsils. Infection at these sites is usually associated with substantial systemic absorption of toxin. The onset of pharyngitis is insidious. Early symptoms include malaise, sore throat, anorexia, and low-grade fever. Within 2–3 days, a bluish-white membrane forms and extends, varying in size from covering a small patch on the tonsils to covering most of the soft palate. Often by the time a physician is contacted, the membrane is greyish-green, or black if bleeding has occurred. There is a minimal amount of mucosal erythema surrounding the membrane. The membrane is adherent to the tissue, and forcible attempts to remove it cause bleeding. Extensive membrane formation may result in respiratory obstruction.

The patient may recover at this point; or if enough toxin is absorbed, develop severe prostration, striking pallor, rapid pulse, stupor, and coma, and may even die within 6 to 10 days. Fever is usually not high, even though the patient may appear quite toxic. Patients with severe disease may develop marked edema of the submandibular areas and the anterior neck along with lymphadenopathy, giving a characteristic “bullneck” appearance.

## Laryngeal Diphtheria

Laryngeal diphtheria can be either an extension of the pharyngeal form or can only involve this site. Symptoms include fever, hoarseness, and a barking cough. The membrane can lead to airway obstruction, coma, and death.

## Cutaneous (Skin) Diphtheria

In the United States, cutaneous diphtheria has been most often associated with homeless persons. Skin infections are quite common in the tropics and are probably responsible for the high levels of natural immunity found in these populations. Skin infections may be manifested by a scaling rash or by ulcers with clearly demarcated edges and membrane, but any chronic skin lesion may harbor *C. diphtheriae* along with other organisms. Generally, the organisms isolated

from recent cases in the United States were nontoxigenic. The severity of the skin disease with toxigenic strains appears to be less than in other forms of infection with toxigenic strains. Skin diseases associated with nontoxigenic strains are no longer reported to the National Notifiable Diseases Surveillance System in the United States.

Other sites of involvement include the mucous membranes of the conjunctiva and vulvovaginal area, as well as the external auditory canal.

## Complications

Most complications of diphtheria, including death, are attributable to effects of the toxin. The severity of the disease and complications are generally related to the extent of local disease. The toxin, when absorbed, affects organs and tissues distant from the site of invasion. The most frequent complications of diphtheria are myocarditis and neuritis.

Myocarditis may present as abnormal cardiac rhythms and can occur early in the course of the illness or weeks later, and can lead to heart failure. If myocarditis occurs early, it is often fatal.

Neuritis most often affects motor nerves and usually resolves completely. Paralysis of the soft palate is most frequent during the third week of illness. Paralysis of eye muscles, limbs, and diaphragm can occur after the fifth week. Secondary pneumonia and respiratory failure may result from diaphragmatic paralysis.

Other complications include otitis media and respiratory insufficiency due to airway obstruction, especially in infants.

## Death

The overall case-fatality rate for diphtheria is 5%–10%, with higher death rates (up to 20%) among persons younger than 5 and older than 40 years of age. The case-fatality rate for diphtheria has changed very little during the last 50 years.

## Laboratory Diagnosis

Diagnosis of diphtheria is usually made on the basis of clinical presentation since it is imperative to begin presumptive therapy quickly.

Culture of the lesion is done to confirm the diagnosis. It is critical to take a swab of the pharyngeal area, especially any discolored areas, ulcerations, and tonsillar crypts. Culture medium containing tellurite is preferred because it provides a selective advantage for the growth of this organism.

### Diphtheria Complications

- Most attributable to toxin
- Severity generally related to extent of local disease
- Most common complications are myocarditis and neuritis
- Death occurs in 5%-10%

# Diphtheria

5

## Diphtheria Antitoxin

- Produced in horses
- First used in the U.S. in 1891
- Used only for treatment of diphtheria
- Neutralizes only unbound toxin

A blood agar plate is also inoculated for detection of hemolytic streptococcus. If diphtheria bacilli are isolated, they must be tested for toxin production.

Gram stain and Kenyon stain of material from the membrane itself can be helpful when trying to confirm the clinical diagnosis. The Gram stain may show multiple club-shaped forms that look like Chinese characters. Other *Corynebacterium* species (diphtheroids) that can normally inhabit the throat may confuse the interpretation of direct stain. However, treatment should be started if clinical diphtheria is suggested, even in the absence of a diagnostic Gram stain.

In the event that prior antibiotic therapy may have impeded a positive culture in a suspect diphtheria case, two sources of evidence can aid in presumptive diagnosis: 1) isolation of *C. diphtheriae* from cultures of specimens from close contacts, or 2) a low nonprotective diphtheria antibody titer (less than 0.1 IU) in serum obtained prior to antitoxin administration. This is done by commercial laboratories and requires several days. To isolate *C. diphtheriae* from carriers, it is best to inoculate a Löffler or Pai slant with the throat swab. After an incubation period of 18–24 hours, growth from the slant is used to inoculate a medium containing tellurite.

## Medical Management

### Diphtheria Antitoxin

Diphtheria antitoxin, produced in horses, was first used in the United States in 1891. It is no longer indicated for prophylaxis of contacts of diphtheria patients, only for the treatment of diphtheria. Since 1997, diphtheria antitoxin has been available only from CDC, and only through an Investigational New Drug (IND) protocol.

Antitoxin will not neutralize toxin that is already fixed to tissues, but it will neutralize circulating (unbound) toxin and will prevent progression of disease. The patient must be tested for sensitivity before antitoxin is given. Consultation on the use of diphtheria antitoxin is available through the duty officer at the CDC during office hours (8:00 a.m.–4:30 p.m. ET) at 404-639-3158, or at all other times through CDC's Emergency Operations Center at 770-488-7100.

Persons with suspected diphtheria should be given antibiotics and antitoxin in adequate dosage and placed in isolation after the provisional clinical diagnosis is made and appropriate cultures are obtained. Respiratory support and airway maintenance should also be administered as needed.

## Antibiotics

Treatment with erythromycin orally or by injection (40 mg/kg/day; maximum, 2 gm/day) for 14 days, or procaine penicillin G daily, intramuscularly (300,000 U/day for those weighing 10 kg or less, and 600,000 U/day for those weighing more than 10 kg) for 14 days. The disease is usually not contagious 48 hours after antibiotics are instituted. Elimination of the organism should be documented by two consecutive negative cultures after therapy is completed.

## Preventive Measures

For close contacts, especially household contacts, a diphtheria booster, appropriate for age, should be given. Contacts should also receive antibiotics—benzathine penicillin G (600,000 units for persons younger than 6 years old and 1,200,000 units for those 6 years old and older) or a 7- to 10-day course of oral erythromycin, (40 mg/kg/day for children and 1 g/day for adults). For compliance reasons, if surveillance of contacts cannot be maintained, they should receive benzathine penicillin G. Identified carriers in the community should also receive antibiotics. Maintain close surveillance and begin antitoxin at the first signs of illness.

Contacts of cutaneous diphtheria should be treated as described above; however, if the strain is shown to be nontoxigenic, investigation of contacts can be discontinued.

## Epidemiology

### Occurrence

Diphtheria occurs worldwide, but clinical cases are more prevalent in temperate zones. In the United States during the pretoxoid era, the highest incidence was in the Southeast during the winter. More recently, highest incidence rates have been in states with significant populations of Native Americans. No geographic concentration of cases is currently observed in the United States.

### Reservoir

Human carriers are the reservoir for *C. diphtheriae* and are usually asymptomatic. In outbreaks, high percentages of children are found to be transient carriers.

### Transmission

Transmission is most often person-to-person spread from the respiratory tract. Rarely, transmission may occur from skin lesions or articles soiled with discharges from lesions of infected persons (fomites).


### Diphtheria Epidemiology

- |                    |  |
|--------------------|--|
| • Reservoir        | Human carriers<br>Usually asymptomatic     |
| • Transmission     | Respiratory<br>Skin and fomites rarely     |
| • Temporal pattern | Winter and spring                          |
| • Communicability  | Up to several weeks<br>without antibiotics |


# Diphtheria

5


**Diphtheria - United States, 1940-2007**



**Diphtheria - United States, 1980-2007**



**Diphtheria - United States, 1980-2004  
Age Distribution of Reported Cases**



## Temporal Pattern

In temperate areas, diphtheria most frequently occurs during winter and spring.

## Communicability

Transmission may occur as long as virulent bacilli are present in discharges and lesions. The time is variable, but organisms usually persist 2 weeks or less, and seldom more than 4 weeks, without antibiotics. Chronic carriers may shed organisms for 6 months or more. Effective antibiotic therapy promptly terminates shedding.

## Secular Trends in the United States

Diphtheria was once a major cause of morbidity and mortality among children. In England and Wales during the 1930s, diphtheria was among the top three causes of death for children younger than 15 years of age.

In the 1920s in the United States, 100,000–200,000 cases of diphtheria (140–150 cases per 100,000 population) and 13,000–15,000 deaths were reported each year. In 1921, a total of 206,000 cases and 15,520 deaths were reported. The number of cases gradually declined to about 19,000 cases in 1945 (15 per 100,000 population). A more rapid decrease began with the widespread use of toxoid in the late 1940s.

From 1970 to 1979, an average of 196 cases per year were reported. This included a high proportion of cutaneous cases from an outbreak in Washington State. Beginning in 1980, all cases with nontoxigenic cutaneous isolates were excluded from reporting. Diphtheria was seen most frequently in Native Americans and persons in lower socio-economic strata.

From 1980 through 2004, 57 cases of diphtheria were reported in the United States, an average of 2 or 3 per year (range, 0–5 cases per year). Only 5 cases have been reported since 2000.

Of 53 reported cases with known patient age since 1980, 31 (58%) were in persons 20 years of age or older; 44% of cases were among persons 40 years of age or older. Most cases have occurred in unimmunized or inadequately immunized persons. The current age distribution of cases corroborates the finding of inadequate levels of circulating antitoxin in many adults (up to 60% with less than protective levels).

Although diphtheria disease is rare in the United States, it appears that *Corynebacterium diphtheriae* continues to circulate in areas of the country with previously endemic diphtheria. In 1996, 10 isolates of *C. diphtheriae* were obtained from persons in a Native American community in South Dakota. Eight of these isolates were toxigenic.



# Diphtheria

5

None of the infected persons had classic diphtheria disease, although five had either pharyngitis or tonsillitis. The presence of toxigenic *C. diphtheriae* in this community is a good reminder for providers not to let down their guard against this organism.

Diphtheria continues to occur in other parts of the world. A major epidemic of diphtheria occurred in countries of the former Soviet Union beginning in 1990. By 1994, the epidemic had affected all 15 Newly Independent States (NIS). More than 157,000 cases and more than 5,000 deaths were reported. In the 6 years from 1990 through 1995, the NIS accounted for more than 90% of all diphtheria cases reported to the World Health Organization from the entire world. In some NIS countries, up to 80% of the epidemic diphtheria cases have been among adults. The outbreak and the age distribution of cases are believed to be due to several factors, including a lack of routine immunization of adults in these countries.

## Diphtheria Toxoid

### Characteristics

Beginning in the early 1900s, prophylaxis was attempted with toxin-antitoxin mixtures. Toxoid was developed around 1921 but was not widely used until the early 1930s. It was incorporated with tetanus toxoid and pertussis vaccine and became routinely used in the 1940s.

Diphtheria toxoid is produced by growing toxigenic *C. diphtheriae* in liquid medium. The filtrate is incubated with formaldehyde to convert toxin to toxoid and is then adsorbed onto an aluminum salt.

Single-antigen diphtheria toxoid is not available. Diphtheria toxoid is available combined with tetanus toxoid as pediatric diphtheria-tetanus toxoid (DT) or adult tetanus-diphtheria (Td), and with both tetanus toxoid and acellular pertussis vaccine as DTaP and Tdap. Diphtheria toxoid is also available as combined DTaP-HepB-IPV (Pediatrix) and DTaP-IPV/Hib (Pentacel—see Chapter 14 for more information. Pediatric formulations (DT and DTaP) contain a similar amount of tetanus toxoid as adult Td, but contain 3 to 4 times as much diphtheria toxoid. Children younger than 7 years of age should receive either DTaP or pediatric DT. Persons 7 years of age or older should receive the adult formulation (adult Td), even if they have not completed a series of DTaP or pediatric DT. Two brands of Tdap are available—Boostrix (approved for persons 10 through 64 years of age) and Adacel (approved for persons 11 through 64 years of age). DTaP and Tdap vaccines do not contain thimerosal as a preservative.

### DTaP, DT, Td and Tdap

	Diphtheria	Tetanus
DTaP, DT	7-8 Lf units	5-12.5 Lf units
Td, Tdap (adult)	2-2.5 Lf units	5 Lf units

DTaP and pediatric DT used through age 6 years. Adult Td for persons 7 years and older. Tdap for persons 10-64 years

### Diphtheria Toxoid

- Formalin-inactivated diphtheria toxin
- Schedule Three or four doses + booster  
Booster every 10 years
- Efficacy Approximately 95%
- Duration Approximately 10 years
- Should be administered with tetanus toxoid as DTaP, DT, Td, or Tdap

# Diphtheria

5

## Routine DTaP Primary Vaccination Schedule

Dose	Age	Interval
Primary 1	2 months	---
Primary 2	4 months	4 weeks
Primary 3	6 months	4 weeks
Primary 4	15-18 months	6 months

## Children Who Receive DT

- The number of doses of DT needed to complete the series depends on the child's age at the first dose:
  - if first dose given at younger than 12 months of age, 4 doses are recommended
  - if first dose given at 12 months or older, 3 doses complete the primary series

## Routine DTaP Schedule for Children Younger Than 7 Years of Age

### Booster Doses

- 4 through 6 years of age, before entering school
- 11 or 12 years of age if 5 years since last dose (Tdap)
- Every 10 years thereafter (Td)

## Routine Td Schedule for Unvaccinated Persons 7 Years of Age and Older

Dose*	Interval
Primary 1	---
Primary 2	4 weeks
Primary 3	6 to 12 months

Booster dose every 10 years

\*ACIP recommends that one of these doses (preferably the first) be administered as Tdap

## Immunogenicity and Vaccine Efficacy

After a primary series of three properly spaced diphtheria toxoid doses in adults or four doses in infants, a protective level of antitoxin (defined as greater than 0.1 IU of antitoxin/mL) is reached in more than 95%. Diphtheria toxoid has been estimated to have a clinical efficacy of 97%.

## Vaccination Schedule and Use

DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine) is the vaccine of choice for children 6 weeks through 6 years of age. The usual schedule is a primary series of 4 doses at 2,4,6, and 15–18 months of age. The first, second, and third doses of DTaP should be separated by a minimum of 4 weeks. The fourth dose should follow the third dose by no less than 6 months, and should not be administered before 12 months of age.

If a child has a valid contraindication to pertussis vaccine, pediatric DT should be used to complete the vaccination series. If the child was younger than 12 months old when the first dose of DT was administered (as DTP, DTaP, or DT), the child should receive a total of four primary DT doses. If the child was 12 months of age or older at the time the first dose of DT was administered, three doses (third dose 6–12 months after the second) completes the primary DT series.

If the fourth dose of DT, DTP or DTaP is administered before the fourth birthday, a booster (fifth) dose is recommended at 4 through 6 years of age. The fifth dose is not required if the fourth dose was given on or after the fourth birthday.

Because of waning antitoxin titers, most persons have antitoxin levels below the optimal level 10 years after the last dose. Tetanus toxoid should be given with diphtheria toxoid as Td every 10 years. The first booster dose may be given at 11 or 12 years of age if at least 5 years have elapsed since the last dose of DTP, DTaP, or DT. ACIP recommends this dose be administered as Tdap. If a dose is given sooner as part of wound management, the next booster is not needed for 10 years thereafter. More frequent boosters are not indicated and have been reported to result in an increased incidence and severity of local adverse reactions.

Td is the vaccine of choice for children 7 years and older and for adults. A primary series is three or four doses, depending on whether the person has received prior doses of diphtheria-containing vaccine and the age these doses were administered. The number of doses recommended for children who received one or more doses of DTP, DTaP, or DT before age 7 years is discussed above. For unvaccinated persons 7 years and older (including persons who cannot

document prior vaccination), the primary series is three doses. The first two doses should be separated by at least 4 weeks, and the third dose given 6 to 12 months after the second. For persons 10 years and older ACIP recommends that one of these doses (preferably the first) be administered as Tdap. A booster dose of Td should be given every 10 years. Tdap is approved for a single dose at this time (i.e., it should not be used for all the doses of Td in a previously unvaccinated person 7 years or older). Refer to the pertussis chapter for more information about Tdap.

Interruption of the recommended schedule or delay of subsequent doses does not reduce the response to the vaccine when the series is finally completed. There is no need to restart a series regardless of the time elapsed between doses.

Diphtheria disease might not confer immunity. Persons recovering from diphtheria should begin or complete active immunization with diphtheria toxoid during convalescence.

### **Contraindications and Precautions to Vaccination**

Persons with a history of a severe allergic reaction (anaphylaxis) to a vaccine component or following a prior dose should not receive additional doses of diphtheria toxoid. Diphtheria toxoid should be deferred for those persons who have moderate or severe acute illness, but persons with minor illness may be vaccinated. Immunosuppression and pregnancy are not contraindications to receiving diphtheria toxoid. See pertussis chapter for additional information on contraindications and precautions to Tdap.

### **Adverse Reactions Following Vaccination**

Local reactions, generally erythema and induration with or without tenderness, are common after the administration of vaccines containing diphtheria toxoid. Local reactions are usually self-limited and require no therapy. A nodule may be palpable at the injection site for several weeks. Abscess at the site of injection has been reported. Fever and other systemic symptoms are not common.

Exaggerated local (Arthus-type) reactions are occasionally reported following receipt of a diphtheria- or tetanus-containing vaccine. These reactions present as extensive painful swelling, often from shoulder to elbow. They generally begin 2–8 hours after injections and are reported most often in adults, particularly those who have received frequent doses of diphtheria or tetanus toxoid. Persons experiencing these severe reactions usually have very high serum antitoxin levels; they should not be given

#### **Diphtheria and Tetanus Toxoids Contraindications and Precautions**

- Severe allergic reaction to vaccine component or following a prior dose
- Moderate or severe acute illness

#### **Diphtheria and Tetanus Toxoids Adverse Reactions**

- Local reactions (erythema, induration)
- Fever and systemic symptoms not common
- Exaggerated local reactions (Arthus-type)
- Severe systemic reactions rare

# Diphtheria

5

further routine or emergency booster doses of Td more frequently than every 10 years. Less severe local reactions may occur in persons who have multiple prior boosters.

Rarely, severe systemic reactions such as generalized urticaria, anaphylaxis, or neurologic complications have been reported following administration of diphtheria toxoid.

## Vaccine Storage and Handling

All diphtheria-toxoid-containing vaccines should be stored continuously at 35°–46°F (2°–8°C). Freezing reduces the potency of the tetanus component. Vaccine exposed to freezing temperature should never be administered.

## Suspect Case Investigation and Control

Immediate action on all highly suspect cases (including cutaneous) is warranted until they are shown not to be caused by toxigenic *C. diphtheriae*. The following action should also be taken for any toxigenic *C. diphtheriae* carriers who are detected.

1. Contact state health department or CDC.
2. Obtain appropriate cultures and preliminary clinical and epidemiologic information (including vaccine history).
3. Begin early presumptive treatment with antibiotics and antitoxin. Impose strict isolation until at least two cultures are negative 24 hours after antibiotics were discontinued.
4. Identify close contacts, especially household members and other persons directly exposed to oral secretions of the patient. Culture all close contacts, regardless of their immunization status. Ideally, culture should be from both throat and nasal swabs. After culture, all contacts should receive antibiotic prophylaxis. Inadequately immunized contacts should receive DTaP/DT/Td/Tdap boosters. If fewer than three doses of diphtheria toxoid have been given, or vaccination history is unknown, an immediate dose of diphtheria toxoid should be given and the primary series completed according to the current schedule. If more than 5 years have elapsed since administration of diphtheria toxoid-containing vaccine, a booster dose should be given. If the most recent dose was within 5 years, no booster is required (see the ACIP's 1991 Diphtheria, Tetanus, and Pertussis: *Recommendations for Vaccine Use and Other Preventive Measures* for schedule for children younger than 7 years of age). Unimmunized contacts should start a course of DTaP/DT/Td vaccine and be monitored closely for symptoms of diphtheria for 7 days.
5. Treat any confirmed carrier with an adequate course of antibiotic, and repeat cultures at a minimum of 2 weeks